{"id":622310,"date":"2024-06-24T21:14:46","date_gmt":"2024-06-25T01:14:46","guid":{"rendered":"https:\/\/platohealth.ai\/deals-report-roche-licenses-ascidians-rna-editing-tech-for-neuro\/"},"modified":"2024-06-25T18:12:48","modified_gmt":"2024-06-25T22:12:48","slug":"deals-report-roche-licenses-ascidians-rna-editing-tech-for-neuro","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/deals-report-roche-licenses-ascidians-rna-editing-tech-for-neuro\/","title":{"rendered":"Deals Report: Roche licenses Ascidian\u2019s RNA editing tech for neuro","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
ARTICLE | Deals<\/p>\n
\n By Gunjan Ohri, Data Content Analyst<\/span><\/span>\n<\/p>\n June 25, 2024 1:14 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n The past seven days brought at least two deals that could be worth over $1 billion, with Roche gaining access to a RNA editing technology from Ascidian, and Day One adding an antibody-drug conjugate (ADC) from MabCare.<\/p>\n Roche <\/b>(SIX:ROG; OTCQX:RHHBY) paid $42 million up front to use<\/span> Ascidian Therapeutics Inc.<\/a><\/b>\u2019s RNA exon editing platform to create therapies against undisclosed neurological disease targets. Ascidian\u2019s technology<\/span> enables correction of disease-causing mutations via pre-mRNA trans-splicing<\/a>, which promises durable results while avoiding the risks of permanently altering the DNA via conventional gene editing. Ascidian, which is eligible for up to $1.8 billion in milestones, will conduct discovery and certain preclinical activities with Roche, after which the pharma will take over…<\/p>\n ARTICLE | Deals Plus: Day One adds PTK7 ADC from MabCare, and updates from Sanofi-Belharra and more By Gunjan Ohri, Data Content Analyst June 25, 2024 1:14 AM UTC The past seven days brought at least two deals that could be worth over $1 billion, with Roche gaining access to a RNA editing technology from Ascidian, […]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":622314,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[50],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/622310"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=622310"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/622310\/revisions"}],"predecessor-version":[{"id":622313,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/622310\/revisions\/622313"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/622314"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=622310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=622310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=622310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/span><\/div>\n
\n